Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530

Tumour-cell invasion and migration: diversity and escape mechanisms

Friedl, P., & Wolf, K. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1075 · Cited by 3,225 · see citing works

Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome

Lozzio, C., & Lozzio, B. (1975) · Blood · doi:10.1182/blood.v45.3.321.bloodjournal453321 · Cited by 2,978 · see citing works

Cellular functions regulated by Src family kinases.

Thomas, S. M., & Brugge, J. (1997) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.13.1.513 · Cited by 2,610 · see citing works

The Conformational Plasticity of Protein Kinases

Huse, M., & Kuriyan, J. (2002) · Cell · doi:10.1016/s0092-8674(02)00741-9 · Cited by 1,760 · see citing works

Compensation mechanism in tumor cell migration

Wolf, K., Mazo, I. B., Leung, H. C. H., Engelke, K., von Andrian, U. H., Deryugina, E. I., Strongin, A. Y., Bröcker, E., & Friedl, P. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200209006 · Cited by 1,392 · see citing works

Discovery of N -(2-Chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a Dual Src/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclinical Assays

Lombardo, L. J., Lee, F. Y., Chen, P., Norris, D. J., Barrish, J. C., Behnia, K., Castaneda, S., Cornelius, L. A. M., Das, J., Doweyko, A. M., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049486a · Cited by 1,303 · see citing works

Protein Kinase Inhibitors: Insights into Drug Design from Structure

Noble, M. E. M., Endicott, J., & Johnson, L. N. (2004) · Science · doi:10.1126/science.1095920 · Cited by 1,207 · see citing works

Src family kinases in tumor progression and metastasis

Summy, J. M., & Gallick, G. E. (2003) · Cancer and Metastasis Reviews · doi:10.1023/a:1023772912750 · Cited by 827 · see citing works

Selective Requirement for Src Kinases during VEGF-Induced Angiogenesis and Vascular Permeability

Eliceiri, B. P., Paul, R., Schwartzberg, P. L., Hood, J. D., Leng, J., & Cheresh, D. A. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80221-x · Cited by 814 · see citing works

AZD2171: A Highly Potent, Orally Bioavailable, Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for the Treatment of Cancer

Wedge, S. R., Kendrew, J., Hennequin, L. F., Valentine, P. J., Barry, S. T., Brave, S. R., Smith, N. R., James, N. H., Dukes, M., Curwen, J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4409 · Cited by 720 · see citing works

Src in cancer: deregulation and consequences for cell behaviour

Frame, M. C. (2002) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(02)00040-9 · Cited by 682 · see citing works

Activation and suppression of pp60c-src transforming ability by mutation of its primary sites of tyrosine phosphorylation

Kmiecik, T. E., & Shalloway, D. I. (1987) · Cell · doi:10.1016/0092-8674(87)90756-2 · Cited by 623 · see citing works

The hunting of the Src

Martin, G. S. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35073094 · Cited by 599 · see citing works

The pharmacokinetics of Norpace.

Karim, A. (1975) · PubMed · Cited by 554 · see citing works

The interplay between Src and integrins in normal and tumor biology

Playford, M. P., & Schaller, M. D. (2004) · Oncogene · doi:10.1038/sj.onc.1208080 · Cited by 520 · see citing works

Activating SRC mutation in a subset of advanced human colon cancers

Irby, R. B., Mao, W., Coppola, D., Kang, J., Loubeau, J. M., Trudeau, W., Karl, R., Fujita, D. J., Jove, R., & Yeatman, T. J. (1999) · Nature Genetics · doi:10.1038/5971 · Cited by 489 · see citing works

SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.

Golas, J. M., Arndt, K. T., Etienne, C., Lucas, J., Nardin, D., Gibbons, J. J., Frost, P., Ye, F., Boschelli, D. H., & Boschelli, F. (2003) · PubMed · Cited by 412 · see citing works

Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer.

Talamonti, M. S., Roh, M. S., Curley, S. A., & Gallick, G. E. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116200 · Cited by 399 · see citing works

Cell transformation by pp60c-src mutated in the carboxy-terminal regulatory domain

Cartwright, C. A., Eckhart, W., Simon, S., & Kaplan, P. L. (1987) · Cell · doi:10.1016/0092-8674(87)90758-6 · Cited by 390 · see citing works

p27 Phosphorylation by Src Regulates Inhibition of Cyclin E-Cdk2

Chu, I. M., Sun, J., Arnaout, A., Kahn, H., Hanna, W. M., Narod, S. A., Sun, P., Tan, C., Hengst, L., & Slingerland, J. M. (2007) · Cell · doi:10.1016/j.cell.2006.11.049 · Cited by 372 · see citing works

N-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a Novel, Highly Selective, Orally Available, Dual-Specific c-Src/Abl Kinase Inhibitor

Hennequin, L. F., Allen, J. M., Breed, J., Curwen, J., Fennell, M., Green, T. P., der Brempt, C. L., Morgentin, R., Norman, R. A., Olivier, A., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060434q · Cited by 365 · see citing works

Src-induced de-regulation of E-cadherin in colon cancer cells requires integrin signalling

Avizienyte, E., Wyke, A. W., Jones, R. J., McLean, G. W., Westhoff, M., Brunton, V. G., & Frame, M. C. (2002) · Nature Cell Biology · doi:10.1038/ncb829 · Cited by 359 · see citing works

AZD1152, a Selective Inhibitor of Aurora B Kinase, Inhibits Human Tumor Xenograft Growth by Inducing Apoptosis

Wilkinson, R. W., Odedra, R., Heaton, S. P., Wedge, S. R., Keen, N., Crafter, C., Foster, J. R., Brady, M. C., Bigley, A. L., Brown, E., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2979 · Cited by 358 · see citing works

Chemical Inhibitors of Protein Kinases

Bridges, A. J. (2001) · Chemical Reviews · doi:10.1021/cr000250y · Cited by 321 · see citing works

Activation of pp60c-src protein kinase activity in human colon carcinoma.

Bolen, J. B., Veillette, A., Schwartz, A. M., DeSeau, V, & Rosen, N. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.8.2251 · Cited by 299 · see citing works

Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells

Hiscox, S., Morgan, L. D., Green, T. P., Barrow, D., Gee, J. M. W., & Nicholson, R. I. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-9120-9 · Cited by 274 · see citing works

Dasatinib Inhibits Migration and Invasion in Diverse Human Sarcoma Cell Lines and Induces Apoptosis in Bone Sarcoma Cells Dependent on Src Kinase for Survival

Shor, A. C., Keschman, E. A., Lee, F. Y., Muro‐Cacho, C., Letson, G. D., Trent, J. C., Pledger, W. J., & Jove, R. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3469 · Cited by 234 · see citing works

Analysis of pp60c-src protein kinase activity in human tumor cell lines and tissues.

Rosen, N. X., Bolen, J. B., Schwartz, A. M., Cohen, P., DeSeau, V., & Israel, M. A. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)67084-x · Cited by 224 · see citing works

Inhibition of Src Expression and Activity Inhibits Tumor Progression and Metastasis of Human Pancreatic Adenocarcinoma Cells in an Orthotopic Nude Mouse Model

Trevino, J. G., Summy, J. M., Lesslie, D. P., Parikh, N. U., Hong, D. S., Lee, F. Y., Donato, N. J., Abbruzzese, J. L., Baker, C. H., & Gallick, G. E. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.050570 · Cited by 206 · see citing works

Dasatinib (BMS-354825) Selectively Induces Apoptosis in Lung Cancer Cells Dependent on Epidermal Growth Factor Receptor Signaling for Survival

Song, L., Morris, M. D., Bagui, T. K., Lee, F. Y., Jove, R., & Haura, E. B. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4620 · Cited by 203 · see citing works

Src family kinase inhibitor PP2 restores the E-cadherin/catenin cell adhesion system in human cancer cells and reduces cancer metastasis.

Nam, J., Ino, Y., Sakamoto, M., & Hirohashi, S. (2002) · PubMed · Cited by 175 · see citing works

[21] Regression analysis, experimental error, and statistical criteria in the design and analysis of experiments for discrimination between rival kinetic models

Mannervik, B. (1982) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(82)87023-7 · Cited by 173 · see citing works

Discovery of a New Class of Anilinoquinazoline Inhibitors with High Affinity and Specificity for the Tyrosine Kinase Domain of c-Src

Plé, P. A., Green, T. P., Hennequin, L. F., Curwen, J., Fennell, M., Allen, J. M., der Brempt, C. L., & Costello, G. F. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030317k · Cited by 170 · see citing works

SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells

Vultur, A., Buettner, R., Kowolik, C. M., Liang, W. P., Smith, D. D., Boschelli, F., & Jove, R. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0126 · Cited by 170 · see citing works

Calpain 2 and Src dependence distinguishes mesenchymal and amoeboid modes of tumour cell invasion: a link to integrin function

Carragher, N. O., Walker, S. M., Carragher, L., Harris, F. M., Sawyer, T. K., Brunton, V., Ozanne, B. W., & Frame, M. C. (2006) · Oncogene · doi:10.1038/sj.onc.1209582 · Cited by 164 · see citing works

Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia

Manley, P. W., Cowan‐Jacob, S. W., & Mestan, J. (2005) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2005.07.040 · Cited by 160 · see citing works

Src and Ras are involved in separate pathways in epithelial cell scattering

Boyer, B., Roche, S., Denoyelle, M., & Thiery, J. P. (1997) · The EMBO Journal · doi:10.1093/emboj/16.19.5904 · Cited by 143 · see citing works

Biosensor Analysis of Drug–Target Interactions: Direct and Competitive Binding Assays for Investigation of Interactions between Thrombin and Thrombin Inhibitors

Karlsson, R., Kullman-Magnusson, M., Hämäläinen, M., Remaeus, A., Andersson, K., Borg, P., Gyzander, E., & Deinum, J. (2000) · Analytical Biochemistry · doi:10.1006/abio.1999.4406 · Cited by 126 · see citing works

Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib

Serrels, A., Macpherson, I. R., Evans, T. R. J., Lee, F. Y., Clark, E. A., Sansom, O. J., Ashton, G. H. S., Frame, M. C., & Brunton, V. G. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0382 · Cited by 124 · see citing works

Increased Src activity disrupts cadherin/catenin-mediated homotypic adhesion in human colon cancer and transformed rodent cells.

Irby, R., & Yeatman, T. J. (2002) · PubMed · Cited by 123 · see citing works

Src kinase contributes to the metastatic spread of carcinoma cells

Boyer, B., Bourgeois, Y., & Poupon, M. (2002) · Oncogene · doi:10.1038/sj.onc.1205298 · Cited by 118 · see citing works

Activation of Rac1 by Paxillin-Crk-DOCK180 Signaling Complex Is Antagonized by Rap1 in Migrating NBT-II Cells

Vallés, A. M., Beuvin, M., & Boyer, B. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405144200 · Cited by 93 · see citing works

Prevention of MKK6-Dependent Activation by Binding to p38α MAP Kinase

Sullivan, J. E., Holdgate, G. A., Campbell, D., Timms, D. A., Gerhardt, S., Breed, J., Breeze, A. L., Bermingham, A., Pauptit, R. A., Norman, R. A., et al. (2005) · Biochemistry · doi:10.1021/bi051714v · Cited by 90 · see citing works

Elevated c-Src is linked to altered cell–matrix adhesion rather than proliferation in KM12C human colorectal cancer cells

Jones, R. J., Avizienyte, E., Wyke, A. W., Owens, D. W., Brunton, V. G., & Frame, M. C. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600594 · Cited by 80 · see citing works

Cell growth, global phosphotyrosine elevation, and c-Met phosphorylation through Src family kinases in colorectal cancer cells

Emaduddin, M., Bicknell, D. C., Bodmer, W. F., & Feller, S. M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712176105 · Cited by 50 · see citing works

Functional dissection of transformation by c‐Src and v‐Src

Oneyama, C., Hikita, T., Nada, S., & Okada, M. (2007) · Genes to Cells · doi:10.1111/j.1365-2443.2007.01145.x · Cited by 47 · see citing works

Targeting Protein Kinases for Bone Disease: Discovery and Development of Src Inhibitors

Metcalf, C. A., van Schravendijk, M. R., Dalgarno, D. C., & Sawyer, T. K. (2002) · Current Pharmaceutical Design · doi:10.2174/1381612023393323 · Cited by 45 · see citing works

EGFR mutants found in non-small cell lung cancer show different levels of sensitivity to suppression of Src: implications in targeting therapy

Fu, Y.-N., Yeh, C.-L., Cheng, H., Yang, C.-H., Tsai, S. F., Huang, S.-F., & Chen, Y.-R. (2007) · Oncogene · doi:10.1038/sj.onc.1210684 · Cited by 37 · see citing works

The pyruvate kinase-coupled assay for ATPases: A critical analysis

Jenkins, W. T. (1991) · Analytical Biochemistry · doi:10.1016/0003-2697(91)90160-u · Cited by 27 · see citing works

Src Family Kinases as Regulators of Angiogenesis: Therapeutic Implications

Lesslie, D. P., & Gallick, G. E. (2005) · Current Cancer Therapy Reviews · doi:10.2174/1573394052952500 · Cited by 12 · see citing works

Inhibition of colon tumor metastasis in an orthotopic nude mouse model with the dual selective Src/Abl kinase inhibitor, AZD0530

Phillips, K. A., Parikh, N. U., Kuwai, T., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.14032 · Cited by 5 · see citing works

585 POSTER The dual specific Src/Abl kinase inhibitor AZD0530 inhibits in vitro growth and induces apoptosis in non-small cell lung cancer lines

Helfrich, B., Frederick, B. A., Raben, D., et al. (2006) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(06)70590-0 · Cited by 1 · see citing works

Inhibition of colon tumor metastasis in orthotopic nude mouse models with the dual-selective Src/Abl kinase inhibitor, AZD0530

Phillips, K. A., Parikh, N. U., Park, S., et al. (2007) · Molecular Cancer Therapeutics · Cited by 1 · see citing works

<scp>F</scp>yn inhibition rescues established memory and synapse loss in <scp>A</scp>lzheimer mice

Kaufman, A. C., Salazar, S. V., Haas, L. T., Yang, J., Kostylev, M. A., Jeng, A. T., Robinson, S. A., Gunther, E. C., van Dyck, C. H., Nygaard, H. B., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24394 · Cited by 314 · see citing works

Targeting Fyn Kinase in Alzheimer’s Disease

Nygaard, H. B. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.06.004 · Cited by 162 · see citing works

Current status of SRC inhibitors in solid tumor malignancies

Puls, L. N., Eadens, M., & Messersmith, W. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0408 · Cited by 158 · see citing works

Does modulation of tau hyperphosphorylation represent a reasonable therapeutic strategy for Alzheimer’s disease? From preclinical studies to the clinical trials

Basheer, N., Smolek, T., Hassan, I., Liu, F., Iqbal, K., Zilka, N., & Novak, P. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02113-z · Cited by 159 · see citing works

Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition

Rexer, B. N., Ham, A.-J. L., Rinehart, C., Hill, S., de Matos Granja-Ingram, N., González-Angulo, A. M., Mills, G. B., Dave, B., Chang, J. C., Liebler, D. C., et al. (2011) · Oncogene · doi:10.1038/onc.2011.130 · Cited by 139 · see citing works

Microglia dysfunction caused by the loss of rhoa disrupts neuronal physiology and leads to neurodegeneration

Socodato, R., Portugal, C. C., Canedo, T., Rodrigues, A., Almeida, T. O., Henriques, J. F., Vaz, S. H., Magalhães, J., Silva, C. M., Baptista, F. I., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107796 · Cited by 94 · see citing works

Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion

Ferguson, J., Arozarena, I., Ehrhardt, M., & Wellbrock, C. (2013) · Oncogene · doi:10.1038/onc.2012.25 · Cited by 68 · see citing works

The molecular rationale of Src inhibition in colorectal carcinomas

Gargalionis, A. N., Karamouzis, M. V., & Papavassiliou, A. G. (2014) · International Journal of Cancer · doi:10.1002/ijc.28299 · Cited by 47 · see citing works

Structure-Based Design of a Potent and Selective Covalent Inhibitor for SRC Kinase That Targets a P-Loop Cysteine

Du, G., Rao, S., Gurbani, D., Henning, N. J., Jiang, J., Che, J., Yang, A., Ficarro, S. B., Marto, J. A., Aguirre, A. J., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01502 · Cited by 39 · see citing works

Paradoxical activation of c-Src as a drug-resistant mechanism

Higuchi, M., Ishiyama, K., Maruoka, M., Kanamori, R., Takaori-Kondo, A., & Watanabe, N. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108876 · Cited by 31 · see citing works

Dual Drug Repurposing: The Example of Saracatinib

Ramos, R., & Vale, N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084565 · Cited by 24 · see citing works

Protein kinase inhibitors as therapeutics in neurodegenerative and psychiatric disorders

Tridente, G., Jana, A., Nath, A., & Ashraf, G. M. (2023) · Receptor Tyrosine Kinases in Neurodegenerative and Psychiatric Disorders · doi:10.1016/b978-0-443-18677-6.00015-4 · Cited by 8 · see citing works

Η έκφραση της Focal Adhesion Kinase, Src kinase και Paxillin σε κυτταρολογικό υλικό ασθενών με νευρoβλάστωμα

Κρατημένος, Π. (2015) · doi:10.12681/eadd/43066

New Insights into FAK Phosphorylation Based on a FAT Domain-Defective Mutation

Fang, X., Liu, X., Yao, L., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107134 · Cited by 18 · see citing works

Κλινική σημασία της έκφρασης των πρωτεϊνών FAK, Src και Paxillin σε ηπατικές μεταστάσεις από ορθοκολικό καρκίνο

Μαντωνάκης, Ε. (2020) · doi:10.12681/eadd/47856

FAK regulates tyrosine phosphorylation of CAS, paxillin, and PYK2 in cells expressing v‐Src, but is not a critical determinant of v‐Src transformation

Roy, S., Ruest, P. J., & Hanks, S. K. (2001) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10025 · Cited by 52 · see citing works

Combined expression of the non-receptor protein tyrosine kinases FAK and Src in primary colorectal cancer is associated with tumor recurrence and metastasis formation

de Heer, P., Koudijs, M. M., van de Velde, C. J. �., Aalbers, R. I. J. M., Tollenaar, R. A. E. M., Putter, H., Morreau, J., van de Water, B., & Kuppen, P. J. K. (2008) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2008.05.003 · Cited by 23 · see citing works